Study Stopped
Site unable to recruit subjects
Pilot Clinical Evaluation of Dozee VS, a Contactless Continuous Vital Parameters Monitoring System in Hospital Patients
DZUSFDA21
2 other identifiers
observational
10
1 country
1
Brief Summary
The Dozee VS device developed by Turtle Shell Technologies Pvt. Ltd., is a contactless continuous vital parameters monitoring system. It is designed for continuous and contactless measurement of Heart Rate (HR) and Respiratory Rate (RR). The device uses the concept of ballistocardiography and deploys piezoelectric sensors to capture the micro-vibrations originating from cardiac contractions, upper respiratory tract activity and body movements. This data is then analyzed by a proprietary algorithm and the values of the vital parameters - Heart Rate (HR) and Respiratory Rate (RR) are generated. The captured vital parameters can be accessed remotely via a dashboard which can be accessed on any web browser and a smartphone application. The sensor sheet is placed below the mattress and captures data while the user is resting or sleeping and does not require a sensor to be fixed to the body. It consists of the following sub - units: Contactless sensor sheet, Dozee Pod with power cord, 5 V USB Power Adapter, Health data compute server and Web Dashboard/Mobile App. This provides a more comfortable solution for long-term continuous patient monitoring. Continuous monitoring of people's vital signs, in particular Heart Rate (HR) and Respiratory Rate (RR), may provide a mechanism to alert doctors or nurses of clinical deterioration. Monitoring people's vital signs outside an ICU often relies on nursing staff conducting checks at set intervals. The device can reduce the workload for nursing staff in non-ICU wards.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Dec 2021
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 29, 2021
CompletedStudy Start
First participant enrolled
December 9, 2021
CompletedFirst Posted
Study publicly available on registry
December 10, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 14, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
April 14, 2022
CompletedJune 3, 2022
May 1, 2022
4 months
November 29, 2021
May 31, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (4)
RMSD of Investigational Device's Heart Rate and Gold Standard Device's Heart Rate
Record heart rate in the investigational device and patient monitor at the same time every 60 seconds. Calculate and compare the root mean square difference (RMSD) per patient and Bland-Alman plot of the heart rate for the investigational device and the gold standard device.
12 months
RMSD of Investigational Device's Respiratory Rate and Gold Standard Device's Respiratory Rate
Record respiratory rate in the investigational device and patient monitor at the same time every 60 seconds. Calculate and compare the root mean square difference (RMSD) per patient and Bland-Alman plot of the respiratory rate for the investigational device and the gold standard device.
12 months
RMSD of Predicate Device's Heart Rate and Gold Standard Device's Heart Rate
Record heart rate in the predicate device and patient monitor at the same time every 60 seconds. Calculate and compare the root mean square difference (RMSD) per patient and Bland-Alman plot of the heart rate for the predicate device and the gold standard device.
12 months
RMSD of Predicate Device's Respiratory Rate and Gold Standard Device's Respiratory Rate
Record respiratory rate in the investigational device and patient monitor at the same time every 60 seconds. Calculate and compare the root mean square difference (RMSD) per patient and Bland-Alman plot of the respiratory rate for the predicate device and the gold standard device.
12 months
Secondary Outcomes (4)
Motion Notification Accuracy - DUI (%)
12 months
Bed Exit Notification Accuracy - DUI (%)
12 months
Motion Notification Accuracy - Predicate (%)
12 months
Bed Exit Notification Accuracy - Predicate (%)
12 months
Other Outcomes (1)
Comparison of RMS values of the two primary objectives
12 months
Study Arms (1)
Single Arm Study (Cohort)
All participants will be on standard telemetry monitoring for Heart Rate and Respiration Rate using the gold standard (Electrocardiography and Capnography respectively). In addition, two contactless monitoring devices will be placed on the patient bed to measure data simulataneously. These devices include EarlySense (USFDA approved ballistocardiography device) and Dozee VS (Investigational Device).
Interventions
All participants will be on standard telemetry monitoring for Heart Rate, Respiration Rate and movements using the gold standard (Electrocardiography and Capnography respectively). In addition, two contactless monitoring devices will be placed on the patient bed to measure data simultaneously. These devices include EarlySense (USFDA approved ballistocardiography device) and Dozee VS (Investigational Device).
Eligibility Criteria
The study will be conducted on 105 subjects in the age group above 18 years regardless of gender. The patients admitted in the hospital will be informed about the study and a written informed consent form will be obtained from them. Dozee will be placed under the mattress of the patient's bed and the data will be collected through the device whenever a patient is on the bed. The research team members responsible for data analysis will have access only to the fully anonymised individual-level data and will be blinded to any other patient data, as well as to the components of the calculated scores in the hospital information system.
You may qualify if:
- Adults Male or female. (Above 18 years of age)
- Provide written informed consent.
- Weight between 40kg/88.18lbs and 120kg/264.55lbs(Above 40 kgs)
- Are located in a non-ICU hospital setting.
- Agree to not eat during the testing period (2hours or 10 hours accordingly)
You may not qualify if:
- Are connected to a device which may interfere with the device monitoring in this study.
- Are receiving any bedside care which may be incompatible with the study procedures.
- A likely need to receive or undergo a procedure during the testing period.
- Cannot accept a nasal cannula, or have a monitor lead placed on the chest.
- Have a significant medical condition in the judgement of the investigator, which may compromise the study testing procedures.
- Prisoners
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Turtle Shell Technologies Pvt. Ltd.lead
- Louisiana State University Health Sciences Center in New Orleanscollaborator
- HealthMindscollaborator
Study Sites (1)
Louisiana State University Health Sciences Center
Shreveport, Louisiana, 71103, United States
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 29, 2021
First Posted
December 10, 2021
Study Start
December 9, 2021
Primary Completion
April 14, 2022
Study Completion
April 14, 2022
Last Updated
June 3, 2022
Record last verified: 2022-05
Data Sharing
- IPD Sharing
- Will not share
IPD are protected under HIPPA Act of 1996.